News and Announcements
4Dx Closes $500k Retail Funding Round to Add to $4M in Wholesale Capital
- Published September 13, 2016 9:26AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Innovative med-tech company 4Dx is a step closer to commercialising its four-dimensional lung imaging technology after successfully closing a $500,000 retail raise fully subscribed. This comes in addition to the company already raising AU$4m in capital from private investors which will be used to advance the business beyond initial FDA clearance early next year.
4Dx’s lung imaging technology has the potential to play a major role in the diagnostics and treatment of respiratory diseases such as asthma, chronic obstructive pulmonary disease, cystic fibrosis and lung cancer.
The close of the retail round brings the total funds invested in this technology to Over $15million which includes backing by 4Dx investors, grants and R&D tax incentives and US$600k from the sales of a pre-clinical scanner to a major U.S Hospital.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
